Results 71 to 80 of about 51,607 (296)

Treatment of central nervous system lymphoma — literature review and own experiences

Онкогематология, 2014
Central nervous system (CNS) involvement in advanced non-Hodgkin’s lymphoma (NHL) occurs in 5–29 % of cases. Primary CNS lymphoma (PLCNS) significantly less revealed: 1–2 % of lymphoma cases and 5 % of all malignant CNS diseases.
S. V. Minenko, Yu. V. Larina, V. V. Ptushkin, N. K. Khuazheva, V. V. Lunin, T. N. Perestoronina, E. R. Biyachuev, A. V. Pshonkin, S. V. Semochkin, Zh. V. Sheikh, V. N. Yakovlev, V. G. Alekseev   +11 more
doaj   +3 more sources

Therapeutic targeting of chromatin alterations in leukemia and solid tumors

International Journal of Cancer, EarlyView.
Abstract Alterations in chromatin conformation and post‐translational modification of histones have become increasingly recognized as critical drivers of cancer development, progression, and therapy resistance. Recent advances in drug development have led to the establishment of several highly selective small molecule inhibitors, several of which are ...
Florian Perner, Tobias Berg, Daniel Sasca, Sophie‐Luise Mersiowsky, Jayant Y. Gadrey, Johanna Thomas, Michael W. M. Kühn, Michael Lübbert   +7 more
wiley   +1 more source

Platelet-derived microparticles enhance Ara-C-induced cell death in acute lymphoblastic leukemia (Nalm-6) [PDF]

BioImpacts
Introduction: The current understanding highlights the intricate relationship between leukemic cells and their microenvironment, emphasizing the significant impact of environmental factors on chemotherapy resistance or sensitivity.
Fariba Nikravesh, Hossein Arezoomand, Roohollah h Mirzaee Khalilabadi, Maryam Nooshadokht, Hajar Mardani Valandani   +4 more
doaj   +1 more source

Clinical Relevance of the Dose of Cytarabine in the Upfront Treatment of Primary CNS Lymphomas with Methotrexate-Cytarabine Combination [PDF]

The Oncologist, 2011
Abstract Background. The combination of high doses of methotrexate (MTX) and cytarabine (araC) is the standard chemotherapy for patients with primary CNS lymphoma (PCNSL). The addition of an alkylating agent could improve MTX-araC efficacy because it is active against quiescent G0 cells and increases ...
Ferreri AJM, Licata G, Foppoli M, Corazzelli G, Zucca E, Stelitano C, Zaja F, Fava S, Paolini R, Franzin A, Politi LS, PONZONI , MAURILIO, Reni M.   +12 more
openaire   +4 more sources

Daunorubicin/Cytarabine Liposome: A Review in Acute Myeloid Leukaemia

Drugs, 2018
VYXEOS™ is a liposomal-encapsulated formulation of daunorubicin and cytarabine delivering a fixed, synergistic 1:5 molar ratio (hereafter referred to as daunorubicin/cytarabine liposome).
Hannah A. Blair
semanticscholar   +1 more source

Model-based optimal AML consolidation treatment [PDF]

arXiv, 2019
Neutropenia is an adverse event commonly arising during intensive chemotherapy of acute myeloid leukemia (AML). It is often associated with infectious complications. Mathematical modeling, simulation, and optimization of the treatment process would be a valuable tool to support clinical decision making, potentially resulting in less severe side effects
arxiv  

BCR::ABL1‐Positive Acute Myeloid Leukemia

American Journal of Hematology, EarlyView.
Alban Canali, Jean‐Baptiste Rieu, Leopoldine Lapierre, Barbara J. Bain   +3 more
wiley   +1 more source

Binding of Released Bim to Mcl-1 is a Mechanism of Intrinsic Resistance to ABT-199 which can be Overcome by Combination with Daunorubicin or Cytarabine in AML Cells

Clinical Cancer Research, 2016
Purpose: To investigate the molecular mechanism underlying intrinsic resistance to ABT-199. Experimental Design: Western blots and real-time RT-PCR were used to determine levels of Mcl-1 after ABT-199 treatment alone or in combination with cytarabine or ...
Xiaojia Niu, Jianyun Zhao, Jun Ma, C. Xie, Holly Edwards, Guan Wang, J. T. Caldwell, Shengyan Xiang, X. Zhang, R. Chu, Z. Wang, Hai Lin, J. Taub, J. Taub, Y. Ge   +14 more
semanticscholar   +1 more source

Nanomaterials for acute myeloid leukemia therapy: Current progress and future perspectives

Interdisciplinary Medicine, EarlyView.
Infographics of this review introducing the current treatment strategies, types of nanomaterials, and their advantages in AML treatment (Created with BioRender.com, a license purchased, accessed on March 26, 2024). Abstract Acute myeloid leukemia (AML) is a highly aggressive hematologic malignancy characterized by poor prognosis, high relapse rates ...
Jiarui Zhao, Jiaqi Cui, Lixuan Wang, Xinyi Shi, Jiayan Ding, Muhammad Farhan Sohail, Irshad Hussain, Qihui Liu, Fangfang Chen   +8 more
wiley   +1 more source

Inhibition of Tunneling Nanotube (TNT) Formation and Human T-cell Leukemia Virus Type 1 (HTLV-1) Transmission by Cytarabine

Scientific Reports, 2018
The human T-cell leukemia virus type 1 (HTLV-1) is highly dependent on cell-to-cell interaction for transmission and productive infection. Cell-to-cell interactions through the virological synapse, biofilm-like structures and cellular conduits have been ...
M. Omsland, C. Pise-Masison, Dai Fujikawa, V. Galli, C. Fenizia, R. W. Parks, B. Gjertsen, G. Franchini, V. Andresen   +8 more
semanticscholar   +1 more source